WASHINGTON (Reuters) - A key U.S. lawmaker said on Thursday he had not yet seen a workable approach to creating an approval pathway for generic versions of expensive biotechnology medicines. House Energy and Commerce Committee Chairman John Dingell said in an interview he was working on the issue but was not ready to embrace any of the various legislative proposals on the medicines, also called biologics.
